SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CEPH
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: harkenman who wrote (121)4/28/1997 11:53:00 PM
From: Michael R   of 998
 
This is old news that I picked up in the library. It appeared in an issue of Script during March.

"D&TB unconvinced by Rilutek data:

The UK Drug & Therapeutics Bulletin has called for more convincing data on the benefits of Rhone-Poulenc Rorer's Rilutek (riluzole) in amyotrophic lateral sclerosis. There is no evidence that the drug improves functional capacity or the quality of life, although it possibly prolongs tracheostomy free survival in some patients, the bulletin notes. It also claimed that Rilutek, which was launched in the UK last August, could cost the NHS 3,700 pounds per patient per year, and says that this money could be better spent improving patient and carer support."

Rilutek may be the only approved drug (for now) - but what good is an approved product if it just isn't going to sell very well? Does RPR have something in the pipeline that is a lot better?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News